文献速递艾滋病与性传播感染

持续性低水平病毒血症预测后续病毒学失败:是否该改变第三个90%目标?

Persistent Low-level Viremia Predicts Subsequent Virologic Failure: Is It Time to Change the Third 90?
PubMed 文献 · Clin Infect Dis · 2019-01-01

非洲队列研究纳入1511名接受ART至少6个月的HIV感染者,评估持续性低水平病毒血症(pLLV)与后续病毒学失败的关系。结果显示pLLV≥200 copies/mL使病毒学失败风险翻倍,建议将病毒抑制目标优化至<200 copies/mL。

要点

  • pLLV≥200 copies/mL与后续病毒学失败风险增加相关。
  • 含蛋白酶抑制剂的ART方案与pLLV风险增加相关。
  • 优化HIV护理应关注病毒载量<200 copies/mL的抑制目标。

核心结论

  • pLLV≥200 copies/mL的参与者后续病毒学失败风险增加,应优化HIV护理以病毒抑制<200 copies/mL为目标。

研究设计与样本

  • 非洲队列研究(African Cohort Study)在乌干达、肯尼亚、坦桑尼亚和尼日利亚的诊所招募HIV感染成人,每6个月评估一次。
  • 纳入1511名接受ART至少6个月且无病毒学失败的参与者,共4382人年随访。

主要发现

  • pLLV<200 copies/mL出现在20%的访视中,而pLLV 200-499和500-999 copies/mL各占2%的访视,且随地点变化显著。
  • 含蛋白酶抑制剂的ART与pLLV风险增加相关。
  • 与不可检测病毒载量相比,pLLV 200-499 copies/mL的病毒学失败风险HR为1.81(95%CI 1.08-3.02),pLLV 500-999 copies/mL的HR为2.36(95%CI 1.52-3.67)。

关键数值与推荐

  • WHO指南将HIV病毒载量<1000 copies/mL作为ART目标。
  • pLLV≥200 copies/mL使病毒学失败风险翻倍(pLLV 200-499:HR 1.81,95%CI 1.08-3.02;pLLV 500-999:HR 2.36,95%CI 1.52-3.67)。

临床怎么用

  • 在非洲背景下,应关注pLLV≥200 copies/mL的HIV感染者,因其后续病毒学失败风险增加。
  • 优化HIV护理应致力于将病毒载量抑制至<200 copies/mL。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: World Health Organization (WHO) guidelines identify human immunodeficiency virus (HIV) viral load <1000 copies/mL as the goal of antiretroviral therapy (ART). However, the clinical implications of viremia below this threshold are unclear in the African context. We examined factors associated with persistent low-level viremia (pLLV) and quantified the risk of subsequent virologic. METHODS: The African Cohort Study enrolled HIV-infected adults at clinics in Uganda, Kenya, Tanzania, and Nigeria, with assessments every 6 months. We evaluated participants prescribed ART for at least 6 months without virologic failure for pLLV. We used multinomial logistic regression to evaluate associations between prespecified factors of interest and 3 levels of pLLV (<200, 200-499, and 500-999 copies/mL). We used Anderson-Gill extended Cox proportional hazards to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for viremia category associations with time to failure. RESULTS: We included 1511 participants with 4382 person-years of follow-up. PLLV <200 copies/mL was observed at 20% of visits while 2% of visits had pLLV 200-499 and 500-999 copies/mL each, with substantial variation by site. Protease inhibitor-containing ART was associated with increased risk of pLLV. Compared to undetectable viral load, pLLV ≥200 copies/mL doubled the risk of developing virologic failure (pLLV 200-499: HR, 1.81 [95% CI, 1.08-3.02]); pLLV 500-999: HR, 2.36 [95% CI, 1.52-3.67]). CONCLUSIONS: Participants with pLLV ≥200 copies/mL were at increased risk of subsequent virologic failure. Optimized HIV care in this setting should target viral suppression <200 copies/mL.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Esber A, Polyak C, Kiweewa F, et al. Persistent Low-level Viremia Predicts Subsequent Virologic Failure: Is It Time to Change the Third 90? Clin Infect Dis. 2019. PMID: 30462188. doi:10.1093/cid/ciy989

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。